Poster 251 Prolotherapy for DeQuervain's Tenosynovitis/Tendonosis: A Case Report

Tseng, Victor; Ibrahim, Victor; Yokel, Nathan R.

doi:10.1016/j.pmrj.2012.09.867

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Corticosteroid injection is then the mainstay of treatment for those patients who do not respond to the above. Other described treatments include: acupuncture [ 8 ], ozone oxygen and hyaluronic acid injections [ 9 ], ultrasound-guided percutaneous needle tenotomy and platelet-rich plasma (PRP) injection [ 10 ], and prolotherapy [ 11 ]. Surgery is reserved for failure of conservative modalities and involves release of the first dorsal compartment.…”

Section: Introductionmentioning

confidence: 99%

The Effectiveness of Corticosteroid Injection for De Quervain’s Stenosing Tenosynovitis (DQST): A Systematic Review and Meta-Analysis

Rowland¹,

Phelan²,

Gardiner³

et al. 2015

TOORTHJ

View full text Add to dashboard Cite

De Quervain’s stenosing tenosynovitis (DQST) treatments include corticosteroid injection around the tendon sheath; however there is some ambiguity concerning the efficacy of this treatment. The aim of this systematic review and meta-analysis is to examine the totality of evidence relating to the use of corticosteroid injection in DQST when compared to placebo or other active treatments. A systematic literature search was conducted in July 2014. Only randomized control trials (RCTs) were included. Outcome measures included impairment, activity limitation and participation restriction. Five RCTs were identified with 165 patients, 88 in the treatment group and 77 in the control group.Patients who received corticosteroid injection (n=142) had a higher rate of resolution of symptoms [RR 2.59, 95% CI: 1.25 to 5.37, p=0.05, I2=62%]. This group reported greater pain relief as assessed by Visual Analogue Scale (VAS) at first assessment [mean difference -2.51, 95% CI: -3.11 to -1.90, p=0.0003, I2=65%] and demonstrated a statistically significant improvement in function (n=78) as measured by the DASH score and Dutch AIMS-HFF score [SMD -0.83, 95% CI: -1.54 to -0.12, p=0.02, I2=48]. This review confirms that corticosteroid injection results in a statistically significant increase in resolution of symptoms, pain relief and increased function in the treatment of DQST.

show abstract

Section: Introductionmentioning

confidence: 99%

The Effectiveness of Corticosteroid Injection for De Quervain’s Stenosing Tenosynovitis (DQST): A Systematic Review and Meta-Analysis

Rowland¹,

Phelan²,

Gardiner³

et al. 2015

TOORTHJ

View full text Add to dashboard Cite

show abstract

“…Other options are acupuncture, ozone therapy, hyaluronic acid injection, USG guided percutaneous needle tenotomy, PRP injection, prolotherapy,etc. [12][13][14][15] Surgery is done if above treatment modalities failed and is done by releasing of the first dorsal compartment.…”

Section: Introductionmentioning

confidence: 99%

Impact of Corticosteroid Injection on The de Quervain’s Tenosynovitis

Morshed¹,

Emran²,

Hasan³

et al. 2021

KYAMC j.

View full text Add to dashboard Cite

Background: de Quervain’s tenosynovitis may be caused by thickened extensor retinaculum which holds the tendon in position in wrist. There are both operative and non-operative treatments for the condition. Corticosteroid injection is a very good conservative treatment option. Objective: To see the outcome of corticosteroid Injection in the de Quervain’s Tenosynovitis. Materials and Methods: This was prospective interventional study conducted at the outpatient department of Kurmitola General Hospital during the period from January 2018 to December 2019. Total 71 patients with de Quervain’s tenosynovitis were analyzed. Secondary outcomes were measured by Visual Analogue Scale (VAS) and Quick Disabilities of Arm, Shoulder and Hand (DASH) score. Results: Among the 71 affected hands, 11 (16.22%) patients had recurred. Sixty (83.78%) patients had no positive sign or symptom after 6 months of follow-up. Average VAS before injection was 8.27±1.23. Post injection VAS was 0.82±1.49 at 1 month follow-up and 1.46±2.34 at 6 month follow-up which was improved significantly. Pre-injection average Quick DASH score was 77.33±13.59 which was reduced to 18.34±12.37 after 1 month and 22.97±17.28 after 6 months of follow-up. Conclusion: Single injection of triamcinolone with local anesthetic for the treatment of de Quervain’s disease was proved significant conservative treatment option though there were few complications and failed cases. We should pay more attention to long-term follow-up and proper injection technique. KYAMC Journal.2021;12(02): 88-91

show abstract

“…5 Other described treatments include acupuncture, 6 ozone oxygen and hyaluronic acid injections, 7 ultrasound-guided percutaneous needle tenotomy and platelet-rich plasma (PRP) injection, 8 and prolotherapy. 9 After failure of all the conservative efforts, surgical release of the first dorsal compartment and decompression of the stenosed APL and EPB tendons are often considered. CS like methylprednisolone, a potent anti-inflammatory, acts locally by inhibiting the early phenomena of the inflammatory process (edema, fibrin deposition, capillary dilation, migration of phagocytes into the inflamed areas and phagocytic activity), and later manifestations (capillary proliferation, fibroblast proliferation, and deposition of collagen) and still later cicatrisation.…”

mentioning

confidence: 99%

Comparison of Clinical and Functional Outcomes after Platelet-Rich Plasma Injection and Corticosteroid Injection for the Treatment of de Quervain's Tenosynovitis

et al. 2022

View full text Add to dashboard Cite

Background Platelet-rich plasma (PRP) has local anti-inflammatory actions, which is being used as a treatment in various tendinopathies. Purpose The aim of the study is to compare the clinical results of PRP injection and corticosteroid injection in the management of de Quervain's tenosynovitis (DQTSV). Patients and Methods In this prospective study, 60 patients of DQTSV, fulfilling the predefined inclusion and exclusion criteria, were randomised into two groups. In group 1 (n = 30), patients received a single injection of autologous PRP and in group 2 (n = 30) they received a single injection of corticosteroid (methylprednisolone). All patients were followed up at 1 month, 3 months, 6 months, and 1 year for evaluation by Finkelstein test, visual analogue scale (VAS), DASH (Disabilities of the Arm, Shoulder and Hand) score, and Modified Mayo Wrist score (MMWS). Results In both the groups improvement occurred in Finkelstein test, VAS score, DASH score, and MMWS which were found to be statistically significant at all points of follow-ups when compared to the pre-intervention values. Comparison of scores between the two groups did not show any statistical significance. No complications were reported in PRP group. Statistically significant complications (p-value = 0.026) like subcutaneous fat atrophy, depigmentation, and temporary increase in pain were seen in eight patients in the corticosteroid group with an overall complication rate of 26.67%. Conclusion Both the modalities are equally effective in the management of DQTSV remittance. PRP is equally effective as corticosteroid in reducing symptoms of first dorsal compartment stenosing tenosynovitis. PRP may have a lower complication profile, however, this benefit should be weighed against the slight increase in cost and time of PRP preparation and injection. Level of evidence - Level 2, prospective comparative study.

show abstract

Poster 251 Prolotherapy for DeQuervain's Tenosynovitis/Tendonosis: A Case Report

Cited by 3 publications

References 0 publications

The Effectiveness of Corticosteroid Injection for De Quervain’s Stenosing Tenosynovitis (DQST): A Systematic Review and Meta-Analysis

The Effectiveness of Corticosteroid Injection for De Quervain’s Stenosing Tenosynovitis (DQST): A Systematic Review and Meta-Analysis

Impact of Corticosteroid Injection on The de Quervain’s Tenosynovitis

Comparison of Clinical and Functional Outcomes after Platelet-Rich Plasma Injection and Corticosteroid Injection for the Treatment of de Quervain's Tenosynovitis

Contact Info

Product

Resources

About